Unlocking the Secrets of Small Caps: Revealing the Driving Forces (SNGX, IFBD, EQ, SNOA, PHUN)

Evaluating a handpicked set of five distinct small-cap companies for the upcoming week demands attention to forthcoming catalysts, spotting breakout opportunities, and understanding resistance zones. Essential tactics involve forecasting upward momentum and identifying key entry points. Maintaining patience is vital to managing risks and handling possible market declines while waiting for confirmation via notable breakout levels.

Soligenix, Inc. (NASDAQ: SNGX) - Soligenix, Inc. shares concluded last week's trading session with a 2% decline, closing at $3.87. Earlier in August, PCG Digital conducted an exclusive interview with Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group and Principal Investigator of Soligenix’s comparative study. Dr. Poligone shared key insights into the promising developments. He discussed the HPN-CTCL-04 study, which compared HyBryte™ to Valchlor®. Preliminary results suggest HyBryte™ is both safe and effective. The study utilized standard CTCL measurements to evaluate the safety and efficacy of the two treatments, with early findings indicating that HyBryte™ performed well in comparison to the FDA-approved, gold-standard Valchlor®. According to Dr. Poligone, "Valchlor® is one of the most frequently used drugs in our clinic. It's a topical chemotherapy applied once daily, but some patients experience allergic reactions, making it intolerable, and others may not respond to it after prolonged use. These challenges highlight the need for alternative treatments." Safety Profile: The HPN-CTCL-02 study focused on the safety profile of HyBryte™, extending observations of its impact on CTCL. Very low levels of HyBryte™ were detected in the bloodstream after application to large body areas, with no observed effects on major organs such as the heart, liver, kidneys, or bone marrow. These results will be presented at the upcoming EORTC CTCL meeting in Lausanne, Switzerland, from October 9-11, 2024. Future Trials: Dr. Poligone also expressed optimism regarding the upcoming confirmatory Phase 3 FLASH2 trial, which will build on the strong results from earlier studies. The positive safety and efficacy data are expected to facilitate recruitment for FLASH2, attracting both new and previous patients eager to try HyBryte™. Soligenix plans to initiate patient enrollment in the confirmatory FLASH 2 study with HyBryte™ by the end of 2024. As we await further updates from the company, we’ll be monitoring the stock for a potential resistance break between $4.00 and $4.05.

--

Infobird Co., Ltd (NASDAQ: IFBD) - Infobird Co., Ltd shares closed last week's trading session at $2.11, marking a nearly 2% increase. In June, the company announced its entry into an equity acquisition agreement with Shangri-La Trading Limited to acquire 65% of Pure Tech Global Limited in a single transaction. Pure Tech, along with its subsidiaries, is a technology company specializing in digital advertising and marketing campaigns. They leverage digital technology to develop effective online marketing strategies for clients. With years of research and development in software and digital marketing, as well as intelligent customer service, Infobird has expanded its presence in the maternal and infant sector, seeking new customer opportunities and enhancing its market competitiveness. In August, the company provided an update, revealing that on July 31, 2024, an amendment to the original equity acquisition agreement was signed. This amendment confirmed that Infobird will still acquire 65% of Pure Tech Global Limited’s issued and outstanding equity. Pure Tech Global Limited indirectly controls Pinmu Century (Beijing) Marketing Technology Co., Ltd and Zhenxi Brand Marketing Consulting (Shanghai) Centre, both variable interest entities, along with their subsidiaries. The total purchase price for the acquisition remains $40 million, including transaction costs, and will be financed through $33 million in cash and a $7 million promissory note. Due to the amendment, the closing date has been extended to October 31, 2024. As we await further updates from the company, we’ll be watching for a potential resistance break at $2.20, especially with increased trading volume.

--

Equillium, Inc. (NASDAQ: EQ) - Equillium, Inc. shares finished last week’s trading session up nearly 3%, closing at $0.86. In August, the company released its financial results for the second quarter of 2024 and provided updates on key corporate and clinical developments. CEO Bruce Steel commented, "We recently shared positive interim results from the Phase 3 EQUATOR study, as reviewed by the Independent Data Monitoring Committee, which raised no concerns regarding safety or futility and recommended that the trial continue as planned." The company has shared this interim data and the committee’s recommendation with its partner, Ono Pharmaceutical, which has until the end of October 2024 to decide whether to acquire Equillium’s rights to itolizumab. If Ono exercises this option, Equillium would receive a one-time payment of JPY 5.0 billion (approximately $35 million as of the August 5, 2024 exchange rate), significantly boosting its cash reserves. The company would also be eligible to receive up to $101.4 million for achieving certain clinical, regulatory, and commercialization milestones, in addition to continued reimbursement for itolizumab-related expenses. Steel also highlighted Equillium’s progress in advancing its multi-cytokine platform. Following positive topline results from the Phase 2 trial of EQ101 in alopecia areata patients, the company is preparing for a Phase 2b placebo-controlled study, which will involve transitioning from intravenous to subcutaneous delivery and refining the dosage. As we await further updates from the company, we are watching for a potential resistance break at $0.90 with increased trading volume. It’s also worth noting that the company has had approval for a reverse stock split since May and has until January 15, 2025, to regain compliance with the Minimum Bid Price Requirement.

--

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) - Sonoma Pharmaceuticals, Inc. shares closed last week down 2%, finishing at $2.78. In September, the company, in partnership with EMC Pharma, LLC, announced a co-marketing agreement to launch and promote an expanded line of prescription and over-the-counter (OTC) eye care products. The new eye care line will also include updated packaging and design for Ocucyn® Eyelid & Eyelash Cleanser. The full product line is set to debut at the American Academy of Ophthalmology's annual meeting in Chicago, taking place from October 18-21, 2024. Sonoma and EMC Pharma have had a distribution agreement in place since 2021, giving EMC Pharma exclusive rights to manage, market, and distribute Sonoma's HOCl-based prescription dermatology and eye care products in the U.S. Also in September, Sonoma received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based solution, which now includes specific OTC indications for the face, eyelid, and eyelashes. With this clearance, Sonoma's Microcyn wound care solution can be used for the OTC management of minor skin abrasions, lacerations, irritations, and intact skin on these areas. Sonoma considers these the strongest OTC eye care claims in the HOCl industry. The new claim regarding facial use also broadens the potential marketing reach for Sonoma's OTC dermatology products. As we await further updates from the company, we will be watching for a potential resistance break around $2.95.

--

Phunware, Inc. (NASDAQ: PHUN) - Phunware, Inc. shares ended last week's trading session at $3.50, up nearly 3%. This month, the company announced the launch of a fully customizable and configurable mobile solution for events, which will debut during IMEX America and the Global Gaming Expo (G2E) in Las Vegas from October 7-10. Phunware is scheduling demos of its latest app features for attendees at both trade shows. The Conference Event Solution is designed to streamline event management while enhancing attendee engagement. It offers a range of popular tools for event organizers and gaming environments, including dynamic wayfinding, mobile engagement messaging, event scheduling, and content management. "Our solution equips event organizers with everything needed to create engaging experiences through our patented interactive maps and targeted messaging from event organizers or sponsors. All of this is supported by real-time analytics, and the technology can also integrate with existing event apps or management platforms," said Donny Neufuss, Senior Director of Business Development at Phunware. "We believe our mobile Conference Event Solution will enable organizers to deliver outstanding, measurable results by transforming physical spaces through mobile technology." IMEX America is a leading trade show in the meetings, incentives, conferences, and events (MICE) industry, bringing together professionals from event planning, hospitality, and tourism. The event will run from October 8-10, 2024, while G2E takes place from October 7-10, 2024. As we await further updates from Phunware, we’ll be monitoring for a potential resistance break between $3.60 and $3.70.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.